Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptor expression and lacks HER2 overexpression or gene amplification. It accounts for 10–15% of incident breast cancers and carries the worst prognosis. TNBC is overrepresented among Black and pre-menopausal women and is associated with significant psychological and treatment-related burdens, including financial toxicity. Like other breast cancers, TNBC is biologically heterogeneous, leading to diverse clinical and epidemiological behaviors, however, unlike the other clinical subtypes, in TNBC we still lack tumor-specific targeted therapy. Early TNBC outcomes have improved due to the intensification of therapies, including improvements in polychemotherapy and the addition of immunotherapy. Future efforts are needed to identify targetable aberrations for specific drug therapy, prevent immune evasion, and increase social-economic support. Given that the name TNBC illustrates its lack of specifically targeted and effective therapy, we look forward to being able to retire the name in favor of a group of targetable entities within what is now called “TNBC”.

*npj Breast Cancer* (2022) 8:95; https://doi.org/10.1038/s41523-022-00468-0

**INTRODUCTION**

Triple negative breast cancer (TNBC), which accounts for 15–20% of incident breast cancers, is the only breast cancer (BC) subtype that lacks targeted treatments. Using clinical assays, TNBC is human epidermal growth factor receptor 2 (HER2) negative and has <1% expression of estrogen receptors (ER) and progesterone receptors (PR) by immunostaining. It is a biologically aggressive tumor, characterized by moderate/high grade and highly proliferative cancer cells, which, together with limited treatment options leads to the poorest prognosis among BC subtypes. TNBC presents most commonly as an invasive ductal carcinoma; however, there are special TNBC histologies that warrant special attention due to different biology and prognosis. For example, low grade adenoid cystic and secretory TNBC carry better prognosis and, unless high risk clinical features exist, may not require systemic chemotherapy. Chemotherapy remains the chief systemic treatment for TNBC despite multiple efforts to discover targetable therapeutic abnormalities. The lack of progress in finding tailored agents for TNBC stands in stark contrast to multiple agents targeting ER and HER2 in those clinical subtypes. With that said, there are notable recent novel therapeutic advances. These include poly adenosine diphosphate–(ADP)-ribose polymerase inhibitors (PARPi) for patients with germline BRCA1/2 mutations (which is especially relevant for TNBC), FDA-approved in 2019 for metastatic disease then in 2021 for early disease as well as the first immunotherapy regimens for TNBC, also approved for metastatic disease beginning in 2019 and for early disease in 2021.

This review is based on a plenary presentation given at the AACR-San Antonio Breast Cancer Research Symposium (AACR-SABCS) in December 2021, in which we describe the historical overview of TNBC, the current therapeutic landscape, and efforts in the development of new treatments that we anticipate will result in improved prognosis and patient, community, and population health impacts.

**HISTORY OF TNBC**

Twenty years ago, new molecular taxonomy using gene expression profiling illustrated that the BC represents several distinct biologic entities that are only in part recapitulated by ER- and HER2 clinical assays. Existing intrinsic and other molecular subtypes of BC have been identified to carry different prognoses and possibly treatment responsiveness; future profiling efforts doubtless with further illuminate this heterogeneity.

**Intrinsic molecular subtypes in TNBC**

Distinct molecular portraits of breast cancer, originally identified as Luminal, HER2-Enriched, Basal-like (BL), and Normal-like breast cancer, were based unsupervised gene expression analysis. Luminal A and B subtypes express keratins 8/18 and ER-related gene clusters, the BL has overexpression of keratin 5, 17 and epithelial grown factor receptors (EGFR)-related genes, and the HER2-Enriched subtype is characterized by expression of Erb-B2-related genes; each of these molecular subtypes can be found within clinical subsets (Fig. 1). About 80% of TNBC are BL, and BL tumors cluster biologically far from the other BC subtypes, making intrinsic subtyping less useful for meaningful subclassification than in the other clinical subtypes. More detailed confirmation of BC heterogeneity has come from multiple efforts to examine DNA, RNA, microRNA, and protein expression patterns through cross-platform analyses such as The Cancer Genome Atlas and METABRIC.

Within-TNBC transcriptomic efforts have further elucidated several molecularly-defined entities. Lehmann and colleagues initially described seven subtypes of TNBC, based on specific clusters of gene expression potentially useful for targeted therapies. These included basal-like (BL1 and BL2) subtypes enriched for proliferation genes, the immunomodulatory (IM) subtype overexpressing immune signaling genes, luminal androgen receptor (LAR) with AR-activated gene expression, mesenchymal (M) and mesenchymal stem-like (MSL) subtypes characterized by cell motility and angiogenesis-related gene expression, respectively, and an unstable subtype not further.
characterizable. These TNBC subclassifications were derived from analyzing bulk surgical samples including both cancer and non-cancer cells creating the tumor environment. Deeper understanding of the immunomodulatory and the MSL subtypes, which reflected not only intrinsic characteristics of cancer cells but also extrinsic signals/elements, including immune and stromal cells, led those investigators to exclude them, thus refining the Lehman cancer classifications into four TNBC types (BL, L, MSL, and )) in a similar within-TNBC effort on 198 tumors, the Brown lab found four subtypes (LAR, MSL, BL-immunosuppressed, and BL-immunoactivated), also with potential subtype-specific therapeutic implications.

Clinical implications of subtypes in TNBC

The introduction into clinical practice of RNA-based assays that subtype BC by intrinsic biology and prognosis is well established for clinical decision-making in early ER+/BC, and recent studies suggest potential value in metastatic, and in clinically HER2-positive disease.

In TNBC, intrinsic subtype profiling at this point has less clear clinical implications. Shepherd and colleagues analyzed pre-treatment early TNBC from CALGB 40603, a neoadjuvant clinical trial testing bevacizumab and/or carboplatin added to a standard anthracycline/paclitaxel regimen, evaluating long term outcomes and possible genomic predictors of outcomes. The investigators did not find significant value of molecular profiling in identifying the benefit of adding platinum agents or in outcome. Although patients whose tumors appeared BL-immunoeactivated achieved a higher pathological complete response (pCR) rate, this improvement did not translate into improved event-free survival (EFS). Similar results were also seen in the metastatic setting. In the TNT trial testing carboplatin versus docetaxel in TNBC in the first-line setting, most TNBC were BL and while non-BL appeared to benefit more from the taxane, these occurred infrequently so are unlikely to be clinically meaningful. Only those with qBRCA1/2 were particularly sensitive to the platinum agent, with 6.8 months of median PFS (vs 4.4m with docetaxel).

The correlation between TNBC and the BL subtype was further defined in a large cohort of 412 TN and 473 BL samples of BC that were molecularly characterized, confirming that triple negative was largely but not exclusively basal-like (60–80%) and that 70% of BL subtype were TNBC. DNA aberrations typical of TNBC were also examined, including TP53 mutations found in more than 80%, MYK amplification in about half, Rb1 loss in 20%, PIK3CA amplifications in 30%, and BRCA1/2 functional loss in about 20%. Among all these aberrations, only PIK3CA and BRCA1/2 can be considered clinically actionable ESCAT I or II abnormalities. However, valuable biologic information is not limited to DNA and RNA, new data are emerging from proteomic/proteogenomic studies that may aid in identifying therapeutically-relevant vulnerabilities in TNBC.

TUMOR MICROENVIRONMENT OF TNBC

The initial and subsequent modification of the Lehman classifier performed on bulk tumor described above highlighted that non-cancer cells contribute significantly to gene expression profiles and modify treatment response and prognosis of TNBC. The dynamic interactions between cancer cells and the immune system, originally referred to as “immune surveillance”, illustrate the importance that each component of the tumor microenvironment has on behavior and prognosis. Over time, this theory has been extended to the tumor “immunoediting” model which includes three phases: the elimination phase, in which the innate and adaptive immune system identifies and destroys tumor cells (the real “immune surveillance”); the equilibrium phase, in which the immune system maintains control over cancer cells with a balance between the production of immunostimulants (e.g., interleukin [IL] 12) and immunosuppressants (e.g., IL23) and the escape phase, in which the tumor cells escape suppression by the immune system, leading to tumor progression. Since these findings, the ability to evade immune suppression, involving all these external cellular and humoral elements, has become a hallmark of cancer. BC is less immune-activated than many other “hot” tumor types, such as melanoma, bladder or some lung cancers, in part related to fewer immunogenic tumor antigens and non-synonymous (amino acid-altering) mutations. Even if TNBC is the most immune-activated subtype among all BC, as determined by not only immune gene expression but also levels of intra-tumoral and stromal tumor-infiltrating lymphocytes (TILs), not all patients benefit from immunotherapy. How best to define immune activation is a work in progress; current approaches include the presence of TILs, expression of the programmed death-ligand 1 (PD-L1) protein, immune gene signatures, RNA expression of individual immune genes, and immune cell clonality (Tcells and Bcells) studies.

Tumor infiltrating lymphocytes (TILs)

TILs include many types of immune cells infiltrating the tumor with varying density and localization. The most representative are CD8+ T cells, the main effectors of the immune response, CD4+ T helper cells, natural killer cells, M1 macrophages, and dendritic cells (DCs). Regulatory T cells, M2 macrophages, and immature DCs can conversely create an immune escape tumor microenvironment that correlates with worse prognosis. Stromal and epithelial TILs, easily measured in hematoxylin and eosin (H&E)-stained slides, vary widely within TNBC and their activity in the immune-surveillance are influenced by individual immune cell gene expression, soluble factors such as interferon release, and somatic, epigenetic or germline mutations. Their presence in the tumor microenvironment has been validated as an independent good prognostic factor in both chemotherapy-pretreated and untreated patients with early TNBC. Quantitative levels of TILs correlate linearly with lower risk for recurrence or death. In a large cohort of patients with TNBC treated with adjuvant chemotherapy, each 10% of increased TILs (intra-tumoral or stromal) corresponded to an approximately 15% reduction of risk for recurrence. Higher TILs also predicts response to neoadjuvant chemotherapy. In the subgroup of TNBC within a large pooled analysis of 3771 samples.
from neoadjuvant trials, tumors with high TILs (>60% immune cells in the stromal tissue within the tumor) achieved 50% pathologic complete response (pCR) rate compared with 31% in those with lower TILs. Moreover, higher pCR rates were observed in patients with high TILs in a trial adding carboplatin to a neoadjuvant anthracycline and taxane regimen versus the non-carboplatin, suggesting that TILs might predict benefit to specific chemotherapy agents, although this interaction was not significant in the TNBC subset.

Other immune biomarkers
In addition to known predictive biomarkers of clinical benefit from immunotherapy, such as PDL1 expression and DNA mismatch repair (MMR) alterations, newer biomarkers such as high tumor mutational burden (TMB) may prove useful in TNBC. Frequent genomic alterations seen in TNBC may contribute to altered immune response, such as TP53 mutation or deletion of 17p that reduce innate immune signaling and immune T cell infiltration, respectively. A subanalysis of TCGA and METABRIC data found that immune-enriched TNBC were more likely to have lower somatic copy number alteration, lower neoantigen burden, lower clonal heterogeneity, and better prognosis suggestive of effective immune surveillance and elimination. The anti-cancer adaptive immune response is not mediated only by T cells. The presence of clonally (and not subclonal) expanded B cell TILs, enriched for B cell-receptors (BCR) somatic hypermutation, mostly observed in tumor microenvironment of BL and HER2-enriched subtypes from mRNA sequencing, is also related to improved outcomes.

Spatial approaches
Emerging data suggest that merely the number and the immune phenotype of TILs are not enough to define tumor immune activation, that spatial relationships among cancer and immune cells are equally important. A recent study using laser capture microdissection gene expression profiles classified four different immune-tumor microenvironment (TME) subtypes, including the "inflamed" subtype, characterized by CD8+ T cells distributed in both epithelial and stromal tumor compartments and high immune gene expression, compared with the less immune-activated margin and stroma restricted-TME subtypes, and the least immune-activated group, the "immune desert", in which there were few CD8+ T cells at all, and only at the margin.

Newer technologies that allow improved visualization of cellular compartments within a tumor, the importance of both cell type and localization in prognosis and prediction of drug benefit is becoming clearer. One recent study of TNBC patients treated with neoadjuvant chemotherapy found that PDL1 expression and closer spatial relationships of tumor cells to T cells independently predicted pCR.

CLINICAL AND RELAPSE FEATURES
BC is the most common tumor and the main cause of cancer-related mortality worldwide; TNBC is about 15-20% among all. Epidemiology, distribution and mortality from TNBC varies within populations based on race or country of origin. In the prospective population-based study in North Carolina, the Carolina Breast Cancer Study (CBCS), designed to oversample Black and premenopausal women with newly diagnosed BC, it was observed that patients with TNBC were far more likely to be Black, younger than those with other subtypes, had tumors diagnosed at higher stage, and those tumors were mostly high-grade. This racial and age distribution was confirmed and extended in CBCS3, in which intrinsic subtyping revealed that a young Black woman was more than twice (37 vs 15%) as likely to have a BL tumor (the intrinsic molecular subtype comprising the majority of TNBC) as an older white woman.

The aggressive biological and clinical behavior of TNBC translates into more frequent and earlier relapses than other subtypes of BC. It is well established that the risk of early distant recurrence within five years of diagnosis is nearly three-fold higher for TNBC compared with non-TNBC. Conversely, the risk of late relapse after 5 years is less than 3%. The most common sites of relapses are lung, lymph nodes and brain (in which early or late involvement occurs in approximately 10 and 40%, respectively). Optimizing treatment for patients with brain metastases remains an unmet need.

RECENT ADVANCES IN EARLY TNBC
The risk of relapse from TNBC has decreased with improved overall treatment and better chemotherapy regimens (Fig. 3), even...
in the pre-immunotherapy and capecitabine era. In a British Columbia registry, the risk of relapse from TNBC decreased by 25–40% between 1986–1992 and 2004–2008\(^5\). Chemotherapy advances, which improved outcomes among all BC patients, particularly improved outcomes in TNBC. This includes the sequential addition of taxanes\(^6\) and the introduction of dose-dense schedules\(^7\). The possibility to de-escalate to less toxic regimens omitting the anthracycline component in TNBC is still controversial. A benefit in 4-year invasive DFS of an anthracycline/taxane regimen (AC-T) versus taxane plus cyclophosphamide (TC, given for six cycles) was seen in the approximately 1300-patient TNBC subset of the phase III ABC trials. Counter to this, the small 100-patient NeoSTOP trial randomized patients to an anthracycline/taxane regimen versus taxane plus carboplatin, finding similar pCR rates, and a meta-analysis based on the PlanB/SUCCESS-C trials, which included a similar subset of TNBC patients as in the ABC trials, compared AC-T to six cycles of TC finding, no difference in five-year DFS\(^8\)–\(^10\).

### Chemotherapy timing and tailoring

Among the most important recent advances for TNBC patients is the use of neoadjuvant chemotherapy, which increases the percentage of patients eligible for breast cancer conservation surgery and for de-escalation of axillary surgery\(^11\). In CALGB 40603, among TNBC patients with pre-treatment clinically positive nodes, 67% had pathologic nodal clearance, potentially avoiding axillary surgery and for de-escalation of axillary surgery\(^12\). In CALGB 40603, among TNBC patients with pre-treatment clinically positive nodes, 67% had pathologic nodal clearance, potentially avoiding axillary node dissection\(^13\). The benefit of neoadjuvant chemotherapy is not only in surgical outcomes but also in the ability to tailor therapy based on pCR. There is a particularly strong relationship in TNBC between pCR and increased EFS (Fig. 4).

As noted in Fig. 4, those patients with residual disease after chemotherapy-based neoadjuvant treatment still have an unacceptably high relapse rate, even in the more recent trials using ICI. The CREATE-X trial changed clinical practice for this group of patients by escalating post-neoadjuvant treatment by adding 4–6 cycles of adjuvant capecitabine, which resulted in an absolute benefit in the TNBC subset in terms of DFS and OS of 14 and 8%, respectively\(^14\). Similar results of adjuvant low dose capecitabine in TNBC were seen in SYSUCC-001 trial\(^15\). It should be noted that both studies enrolled Asian patients that have different dihydropyrimidine dehydrogenase genotype and phenotype than non-Asian population\(^16\). On the contrary, no improvement of DFS was observed adding adjuvant capecitabine after standard chemotherapy in a TNBC GEICAM trial\(^17\).

**PARP inhibitors**

One example of targeted therapy relevant in early TNBC is the use of the PARP inhibitor olaparib in patients with germline mutations in *BRCA1/2* (gBRCA1/2) early BC. This class of drugs acts in tumors with loss of homologous recombination (HR), which is a *BRCA1/2*-dependent function. Through synthetic lethality, by inhibiting PARP-mediated single strand DNA repair, cells with HR-deficiency die. The OlympiA trial demonstrated a 9% difference in 3-year invasive disease-free survival (iDFS) in favor of 1 year of adjuvant olaparib vs placebo in patients with high risk HER2-negative and gBRCA1/2-positive BC who had completed standard chemotherapy. More than 80% of enrolled patients had TNBC\(^18\). Based on metastatic data, it is assumed but not yet proven that this effect would be seen also in the less-common germline PALB2 or somatic *BRCA1/2* mutation-associated tumors\(^19\). PARP inhibitor (talazoparib) was studied also as neoadjuvant treatment in similar population of newly diagnosed TNBC, yielding 45% pCR rates with a single agent, similar to what would be expected with polychemotherapy (45%)\(^20\). In the TNBC subset of a small randomized phase II trial, GeparOla, paclitaxel plus olaparib had similar pCR rate, and better toxicity, as paclitaxel plus carboplatin in patients with early somatic or gBRCA1/2 mutated BC\(^21\). Additional efficacy was not seen by adding PARP inhibitors to standard chemotherapy, for example, veliparib combined with anthracycline/taxane/platinum chemotherapy in BrightNess did not improve pCR or EFS\(^22\).

**Immune checkpoint inhibitors (ICI)**

The most recent advance in early TNBC is the advantage in both pCR, and now demonstrated for EFS, of adding ICI to standard neoadjuvant chemotherapy. Unlike metastatic disease, the benefit of adding ICI is not limited to PD-L1-positive tumors in early TNBC. KEYNOTE 522 was a large practice-changing trial that was unusual in that it was powered for both pCR and EFS endpoints. It enrolled patients with high risk early TNBC, most of whom were PD-L1 positive, to receive four standard chemotherapy drugs with or without pembrolizumab and then postoperatively continue ICI in that arm\(^23\). The dual primary endpoints were met with an absolute benefit in terms of pCR and 3y-EFS of about 7%, at the cost of a higher percentage of grade 3 immune-related toxicities (15 vs 29%)\(^24\). The IMPassion 031 trial was consistent, demonstrating increased pCR by adding atezolizumab to nab-paclitaxel followed by anthracycline and cyclophosphamide (AC). In this trial, as in others, there was higher pCR rates in both chemotherapy alone and chemotherapy plus ICI arms in PD-L1-positive than PD-L1-
negative. In other words, in TNBC, PDL1 is a predictive biomarker for both chemotherapy and ICI. The chemotherapy drug backbone and the timing, sequence, and duration of ICI administration may modify outcomes and treatment response; the optimal combination and endpoints are not yet clear. For example, in the small GeparNuevo the administration of durvalumab alone before start of chemotherapy appeared to provide the same benefit of ICI as in KEYNOTE 522, without the adjuvant ICI 66. There are multiple ongoing trials also examining ICI plus chemotherapy in the adjuvant setting.

RECENT ADVANCES IN METASTATIC TNBC

Unlike other subtypes and the early setting, few therapeutic approaches have been shown to improve survival for patients with metastatic TNBC. With a deeper understanding of biological, molecular, immunological, microenvironmental, and clinical features novel agents have been developed to treat patients with TNBC, and promising agents are on the way (Fig. 5).

Antibody drug conjugates (ADC)

It is becoming clear that ADCs are the wave of the future for how we can give chemotherapy (and other payloads) in a targeted fashion that minimizes the toxicities. These agents have changed the history of HER2+ breast cancer, and the ADC sacituzumab govitecan is effective in TNBC.

Saituzumab govitecan is an ADC made up of an antibody against anti-human trophoblast cell-surface antigen 2 (TROP2) linked to the irinotecan derivative SN-38 as payload by a hydrolysable linker with a high drug-to-antibody ratio (DAR) of 7.567. In the phase III ASCENT trial, this ADC improved progression-free survival (PFS) (5.6 vs 1.7 m) and OS (12.1 vs 6.7 m) compared to physician's choice chemotherapy in patients with metastatic TNBC who did not have brain metastases68. This benefit was, not surprisingly, correlated to TROP2 level expression on the tumor69. Lots of other ADCs are in development (Table1), and another TROP2-ADC, datotematap deruxtecan (Dato-DXd, DS-1062a) 70, demonstrated activity in a small cohort of pretreated TNBC, including those who had previously received sacituzumab govitecan, with an overall response rate (ORR) of 35%71. Similar ORR was seen with trastuzumab deruxtecan (T-DXd) in pretreated patients with a new pathologic classification, “HER2-low”, meaning HER2-negative on clinical assays but with some low levels of expression (HER2 IHC score of 1+ or 2+/ISH negative) – 45% of which were TNBC72. The definitive phase III trial, DESTINY Breast 04 (DB04), compared T-DXd to treatment of
physician’s choice (TPC), and recently demonstrated that T-DXd outperformed TPC in the ITT population, which included patients with HER2-low TNBC or hormone receptor-positive HER2-negative BC. Most TNBC have high expression of LIV1, a protein key to transformation from an epithelial to a more motile mesenchymal cell. An ADC, ladiratuzumab vedotin (LV), is composed of anti-LIV1 antibody linked to an antimicrotubule agent, monomethyl auristatin E. In a phase 1 trial, LV resulted in an approximately 30% ORR in a heavily pretreated subgroup of TNBC patients. Even higher ORR was reached by combining LV with pembrolizumab as first-line treatment in a very small cohort of TNBC patients. Based on preclinical evidence of synergy between ADC and PARPi or ICI, other ongoing trials are focused on these combinations (Table 1).

Table 1. Ongoing trials of antibody drug conjugates in TNBC.

| Drug | Target | Antibody | Drug combined | Study phase | Clinicaltrial.gov |
|------|--------|----------|---------------|-------------|------------------|
| Datopotamab deruxtecan (Dato-DXd) | TROP2 | Datopotamab | Single agent | I | NCT03401385 |
| Sacituzumab govitecan (IMMU-132) | TROP2 | Sacituzumab | Single agent | III | NCT04595565a |
| Ladiratuzumab vedotin (SGN-LV1a) | LIV1 | Ladiratuzumab | Single agent | I | NCT01969643(excluded part B and E) |
| SKB264 | TROP2 | Patritumab | Single agent | II | NCT04965766 |
| Patritumab Deruxtecan (U3-1402) | HER3 | Patritumab | Single agent | II | NCT04152499 |
| Trastuzumab Deruxtecan (T-DXd) | HER2 | Trastuzumab | Single agent | Ib | NCT04556773d |
| Zilovertamab Vedotin (MK-2140) (VLS-101) | ROR1 | Zilovertamab | Single agent | II | NCT04504916 |
| Enfortumab Vedotin | nectin-4 | Enfortumab | Single agent | II | NCT04225117 (Cohort 2) |
| SGN-CD228A | Melanotransferrin (CD228) anti-CD228 | Anti-CD228 | Single agent | I | NCT04042480c |
| ASN004 | ST4 oncofetal antigen (trophoblast glycoprotein) | Anti-ST4 | Single agent | I | NCT04410224 |
| CX-2009 | CD166 | Anti-CD166 | Single agent | II | NCT04596150 (Arm B) |
| FDA018-ADC | TROP2 | Anti-TROP2 | Single agent | I | NCT05174637 |
| OBT076 (MEN1309) | CD205 | Anti-CD205 | Single agent | I | NCT04064359e |
| MRG002 | HER2 | anti-HER2lgG1 | Single agent | II | NCT04742153d |
| NBE-002 | ROR1 | Anti-ROR1 | Single agent | I/II | NCT04441099 |
| MORAB-202 | Folate Receptor Alpha (FRα) | Anti-Frα | Single agent | I | NCT04300556 |
| MGC018 | B7-H3 | Anti-B7-H3 | +/- Anti-PD1 (MGA012) | II | NCT03729596 |
| CAB-ROR2-ADC (BA3021) | CAB | Anti-CAR- ROR2 | +/- Pembrolizumab | I/II | NCT03504488 |
| PTK7-ADC (PF-06647020) | PTK7 | Cofetuzumab | + Gedatolisib | I | NCT03243331 |
| Trastuzumab Duocarmazine (SYD985) | HER2 | Trastuzumab | + Paclitaxel | I | NCT04602117 |

*Post-neoadjuvant; **brain metastases; ***in HER2-negative; ****HER2-low; *****Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine.
Specific pathways targeting
DNA aberrations are common in TNBC, and many efforts have focused on targeting specific tumor pathways. Two promising phase II trials were designed to target the phosphoinositide-3-kinase (PI3K) pathway, altered in about 30% of TNBC with preclinical evidence of sensitivity to PI3K inhibitors. The two trials, LOTUS and PAKT, were phase II trials that combined paclitaxel with the AKT inhibitors ipatasertib and capivasertib. These trials demonstrated little benefit with addition of AKT-targeted agents in the overall population, but activity in PIK3CA/AKT/PTEN-altered TNBC. However, in spite of this promise, the phase III IPAtunity130 trial did not confer a benefit of ipatasertib added to paclitaxel as first-line treatment in TNBC with PIK3CA/AKT/PTEN alterations; the analogous phase III trial of capivasertib has not yet reported.

Other studies were designed to target the EGFR signaling pathway that is almost universally activated in the BL-subtype, however an early trial, TBCRC 001, failed to demonstrate an effect of adding the anti-EGFR antibody cetuximab to carboplatin in TNBC patients, and another randomized phase II trial demonstrated only a modest 10% improvement in ORR with the addition of cetuximab to cisplatin. Serial tumor biopsies obtained in TBCRC 001 showed that the EGFR pathway was activated in most of these tumors, but the signaling was ineffective in some tumors, and there were alternative pathways to keep signaling intact despite EGFR inhibition in others. RAS/RAF/MEK pathway activation is another common oncogenic driver. A MEK1/2-inhibitor (trametinib) window-of-opportunity trial in newly diagnosed TNBC demonstrated a strong treatment-adapted bypass response that involved multiple alternative tyrosine kinase signaling pathways. These studies demonstrated that while there are strong preclinical data supporting targeting specific tumor pathways in TNBC, thus far in this highly mutable disease these efforts have not translated in clinical benefits.

PARP inhibition (PARPi) 
Germline (gBRCA1/2) or somatic BRCA1/2 mutation occurs in about 15–20% of TNBC with its hallmark ineffective homologous recombination DNA damage repair. PARPi was first studied in previously treated metastatic patients with gBRCA1 mutation; just under half had TNBC. Talazoparib improved median PFS by 3 months compared with chemotherapy of physician’s choice (TPC). The very similar OlymPiAD trial compared olaparib to TPC in a similar population of largely pretreated gBRCA1/2-mutated metastatic patients with nearly identical results. TPC in both trials did not include standard first-line drugs, particularly platinum, but regardless these lower-toxicity non-chemotherapy options are hugely valuable both in TNBC and non-TNBC gBRCA-associated breast cancer. Similar high responsiveness has been demonstrated with olaparib in the TBCRC 048 trial in germline PALB2 and somatic BRCA1/2. Many efforts center on identifying the “BRCAness” phenotype among sporadic breast cancers with similarities to germline BRCA-associated and sensitivity to PARPi. Previous PARPi trials in wildtype TNBC have been disappointing, but preclinical data suggest that combinations with ICIs could overcome this limited activity. The phase II TOPACIO trial showed promising results (ORR 21%) with a combination of niraparib and pembrolizumab in a small cohort of TNBC of whom about half were germline carriers; it remains unclear how much of the responsiveness was purely attributable to PARPi in gBRCA-associated tumors in that trial. There are several ongoing trials, such as EORTC-1984-BCG (NCT05209529) and DORA (NCT03167619), that will examine this potential synergy.

Androgen receptor targeting 
Various subtyping methods within TNBC consistently identify a subgroup with an expression of the androgen receptor pathway and more luminal features, often called the Luminal Androgen Receptor (AR) molecular subtype. There have been several trials in AR-positive BC (using multiple methods to define positivity), testing AR-inhibitors such as bicalutamide, abiraterone, enzalutamide, and seviteronel. All resulted in mostly clinical benefit (about 20%) as opposed to response. These were all non-randomized trials, so it is hard to distinguish drug effects from natural history in this subgroup of TNBC, but this remains an area of active study and potential for a targeted approach.

Immunotherapy in metastatic TNBC
As tumor aberrations are hard to target, a great deal of research focus has been on the interaction of cancer cells and the microenvironment. ICIs have demonstrated only modest activity as single agents in the metastatic setting, with up to 20% ORR in first-line and lower in later lines of therapy. Unlike early TNBC, and likely reflecting the more immune-suppressive metastatic microenvironment, PDL1 status is predictive of benefit from ICIs. Real benefit of these drugs is limited to the first-line setting and in combination with chemotherapy. The practice changing trial was IMpassion130, which randomized 902 untreated advanced TNBC patients to receive nab-paclitaxel plus atezolizumab (antiPDL1) or placebo, which revealed PFS and OS benefits of 2.5 and 7.5 months, respectively, limited to the PDL1+ subgroup defined as ≥1% PD-L1 expression by Ventana SP142 assay. On the basis of this trial, atezolizumab received accelerated approval from the FDA in 2019; however, this indication was withdrawn in 2021 by the sponsor after the negative phase III Impassion131, which was similar to IMpassion 130 but with a paclitaxel backbone. Adding pembrolizumab to several chemotherapy regimens (nab-paclitaxel, paclitaxel, or gemcitabine/cisplatin) in KEYNOTE 355 improved PFS and OS in chemo-naive-PDL1+ TNBC patients, defined as CPS ≥ 10% PDL1-expression by the Dako 22C3 assay, including patients who relapsed early after adjuvant chemotherapy. In no trial has an impact of immunotherapy in PDL1-negative metastatic patients been observed, and the best chemotherapy combination with ICIs remains an open question. Other immunotherapy approaches such as vaccines, cell therapies and new combinations are being developed to hopefully enlarge the TNBC population who could benefit from immune-based therapy.

TNBC IN THE COMMUNITY
Racial disparities in outcomes and TNBC
As noted, TNBC is more frequent among Black and young women with BC. Using molecular profiling applied to the CBCS dataset, even more striking differences by race are seen; for example, a Black woman under 50 years old at diagnosis has a 37% chance of having Basal-like breast cancer and only 25% chance of having the good-prognosis Luminal A, whereas a White woman over 50 years old has only a 15% chance of having Basal-like and 52% chance of having a Luminal A tumor.

Given that major advances in treatment have largely been seen in the hormone receptor- and HER2-positive clinical subtypes, it is not surprising that TNBC has the poorest prognosis of all BC, contributing to worse outcomes in Black women simply due to the frequency of this subtype. It should be noted that TNBC carries a poorer prognosis in both Black and White women; within-subtype racial disparities are actually greatest among hormone receptor-positive, HER2-negative BC.

P. Zagami and L.A. Carey
npj Breast Cancer (2022) 95
Burden of TNBC

Patients with cancer have to face many concerns after their diagnosis, including costs, the important decision of where and how to be treated, and what can be expected in their future. Beyond the psychological aspects of facing a life-threatening disease and treatment toxicities, another burden of this disease is represented by financial toxicity that particularly affects patients of color across all tumor types\(^9\), and is associated with lower quality of life, distress, treatment delays or discontinuation, and higher mortality\(^9\). Within two years of diagnosis, the negative impact of financial costs is quite substantial as self-reported by all patients with BC enrolled in phase 3 of the CBCS, but even more striking among Black women (58 vs 39% of White women), including income loss, healthcare-related financial and transportation barriers, job loss, and loss of health insurance. Those who were young and those who received chemotherapy, both factors likely enriching further for TNBC, were 10% more likely to experience adverse financial impact\(^9\). Specifically looking at cancer-related job or income loss, which was reported by 38% of over 2400 CBCS participants, Black women and women living in rural neighborhoods all saw greater income reduction from their cancer diagnosis than urban White women\(^9\). These financial adverse events have to be kept in mind due to their impact on treatment choice, compliance, well-being, and on cancer outcomes.

The umbrella term “TNBC” represents a spectrum of tumors that are disparate both from a tumor and from a microenvironmental standpoint. With advances in chemotherapy, and more recently immune checkpoint inhibition, cure rates have improved in early TNBC and are likely to accelerate. Outcomes in metastatic BC are already being altered by new drugs (ADC, PARPi, ICi) but big transformations are still needed. New ideas are emerging that may allow tumor targeting (e.g., epigenetic modulators preventing reprogramming, AR targeting), prevent immune evasion (e.g., DDR1 antibodies, combinatorial immunotherapy) and maybe even prevent TNBC. In addition to considering the need for better and more precise treatment, we must also consider all disease-related burdens, mindful that while TNBC can occur in anyone, it does particularly affect young and Black women and contributes to all kinds of poorer outcomes. The focus must remain on improving treatment, better managing toxicity, and social and financial support for patients with TNBC.

DATA AVAILABILITY

Source data for all tables are provided in the paper. No new datasets have been generated or analyzed for this article.

Received: 1 March 2022; Accepted: 28 July 2022;
Published online: 20 August 2022

REFERENCES

1. Geyer, F. C. et al. The spectrum of triple-negative breast disease. Am. J. Pathol. 187, 2139–2151 (2017).
2. Pareja, F. et al. Triple-negative breast cancer: The importance of molecular and histologic subtyping, and recognition of low-grade variants. npj Breast Cancer 2, 16036 (2016).
3. Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394–2405 (2021).
4. Robson, M. E. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30, 558–566 (2019).
5. Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753–763 (2018).
6. Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44–59 (2020).
7. Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810–821 (2020).
8. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
9. Headley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304.e6 (2018).
10. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
11. Curtis, C. et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).
12. Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 121, 2750–2767 (2011).
13. Lehmann, B. D. et al. Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One 11, e0157368 (2016).
14. Burstein, M. D. et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 21, 1688–1698 (2015).
15. Carey, L. A. et al. Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2– advanced breast cancer. In Presented at: 2021 San Antonio Breast Cancer Symposium; December 7–10, Abstract S52-00 (American Association for Cancer Research (AACR), San Antonio, TX, 2021).
16. Fernandez-Martinez, A. et al. Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant Phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer. J. Clin. Oncol. 38, 4184–4193 (2020).
17. Kalinsky, K. et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N. Engl. J. Med. 385, 2336–2347 (2021).
18. Prat, A. et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies. J. Clin. Oncol. 39, 1458–1467 (2021).
19. Prat, A. et al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. JNCI: J. Natl Cancer Institute 106, dju152 (2014).
20. Shepherd, J. H. et al. CALGB 40603 (Alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. J. Clin. Oncol. https://doi.org/10.1200/JCO.21.01506 (2022).
21. Tutt, A. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial. Nat. Med. 24, 628–637 (2018).
22. Prat, A. et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18, 123–133 (2013).
23. Lawrence, R. T. et al. The proteomic landscape of triple-negative breast cancer. Cell Rep. 11, 630–644 (2015).
24. Krug, K. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a Phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860–867 (2013).
25. Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. New insights into cancer immunoeediting and its three component phases—elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16–25 (2014).
26. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011).
27. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
28. Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a Phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. 2013. J Clin Oncol 31, 860–867 (2013).
29. Deng, L. et al. Immune profiles of tumor microenvironment and clinical prognosis among women with triple-negative breast cancer. Cancer Epidemiol. Biomark. Prev. 28, 1977–1985 (2019).
30. Bianchini, G., de Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer—expanded options, evolving needs. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-021-00565-2 (2021).
31. Park, J. H. et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann. Oncol. 30, 1941–1949 (2019).
32. Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40–50 (2018).
33. Denkert, C. et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor
80. Baselga, J. et al. Randomized Phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 31, 2586–2592 (2013).
81. Zawistowski, J. S. et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. Cancer Discov. 7, 302–321 (2017).
82. Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer 12, 68–78 (2012).
83. Turner, N., Tutt, A. & Ashworth, A. Hallmarks of “BRCAness” in sporadic cancers. Nat. Rev. Cancer 4, 814–819 (2004).
84. Virayak, S. et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 5, 1132 (2019).
85. Traina, T. A. et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J. Clin. Oncol. 36, 884–890 (2018).
86. Bonnefoi, H. et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCIG 12–1). Ann. Oncol. 27, 812–818 (2016).
87. Gucalp, A. et al. Phase (Ph) 2 stage 1 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor, in women with advanced AR+ triple-negative breast cancer (TNBC) or estrogen receptor (ER)+ BC: CLARITY-01. J. Clin. Oncol. 35, 1102–1102 (2017).
88. Gucalp, A. et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin. Cancer Res. 19, 5505–5512 (2013).
89. Chen, D. S. & Mellman, I. Oncology meets Immunology: The cancer-immunity cycle. Immunity 39, 1–10 (2013).
90. Leisha, A. E. et al. LBA16 - IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Ann. Oncol. 31 (Suppl.), S1148 (2020).
91. Miles, D. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann. Oncol. 32, 994–1004 (2021).
92. Cortes, J. et al. Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. In Presented at: SABCS 2021; December 7–10 (American Association for Cancer Research (AACR), San Antonio, TX, 2021).
93. O’Brien, K. M. et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin. Cancer Res. 16, 6100–6110 (2010).
94. Biddell, C. B. et al. Racial and ethnic differences in the financial consequences of cancer-related employment disruption. Front. Oncol. 11, 690454 (2021).
95. Ramsey, S. D. et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J. Clin. Oncol. 34, 980–986 (2016).
96. Wheeler, S. B. et al. Financial impact of breast cancer in black versus white women. J. Clin. Oncol. 36, 1695–1701 (2018).
97. Spencer, J. C. et al. Employment changes following breast cancer diagnosis: The effects of race and place. JNCI: J. Natl Cancer Inst. 112, 647–650 (2020).

ACKNOWLEDGEMENTS

Based on a plenary presentation given by L.A.C. at AACR-San Antonio Breast Cancer Research Symposium (AACR-SABCS) in December 2021. Thanks to the National Cancer Institute (NCI) Breast SPORE program (P50-CA58223), Susan G Komen and Breast Cancer Research Foundation (L.A.C.), and Ermenegildo Zegna scholarship (P.Z.) that supported this work.

AUTHOR CONTRIBUTIONS

P.Z. and L.A.C. conceived and drafted the manuscript. P.Z. designed and finalized table and figures. L.A.C. supervised the work. All the authors read and approved the final version of the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Lisa Anne Carey.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022